ResultsIQ

ResultsIQ › Latest results › TruAlt Bioenergy Limited

TruAlt Bioenergy Limited Q1 FY27 results deck summary

NSE: TRUALT · BSE: 544545

Results deck of 28 Jul 2026, summarised by AI from the filing.

CBG Units 1-4 capacity ramp-up guided at FY27 40%, FY28 85%, FY29 onwards ~90%, with phased commissioning aligned with demand visibility and CGD offtake.

Key takeaways

  1. CBG ramp-up CBG Units 1-4 capacity ramp-up guided at FY27 40%, FY28 85%, FY29 onwards ~90%, with phased commissioning aligned with demand visibility and CGD offtake.
  2. Dual-feed integration Installed ethanol capacity increased 43% from 1,400 KLPD in Q1 FY26 to 2,000 KLPD in Q1 FY27, with 1,300 KLPD (65%) now on dual-feed technology.
  3. Grain profitability Grain-based operations generated approximately 6% higher profitability than sugar-based operations, driving expansion in EBITDA and PBT margins.

Original filing on BSE

TruAlt Bioenergy Limited Q1 FY27 results

As filed: Revenue ₹627 cr (+106% year on year), EBITDA ₹133 cr (+216% year on year), PAT ₹59.3 cr (+300% year on year), EBITDA margin 21.2% (+736 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹603 cr, EBITDA ₹131 cr, PAT ₹56.7 cr, EBITDA margin 21.7%. Not scored. No result for the same quarter last year. Share price after the results: −0.7% in 28 days (Nifty 500: +2.2%).
  • Q3 FY26: Revenue ₹703 cr, EBITDA ₹129 cr, PAT ₹66.0 cr, EBITDA margin 18.4%. Not scored. No result for the same quarter last year. Share price after the results: −6.8% in 30 days (Nifty 500: −3.2%).
  • Q2 FY26: Revenue ₹104 cr, EBITDA −₹12.0 cr, PAT −₹43.0 cr, EBITDA margin -11.5%. Not scored. No result for the same quarter last year. Share price after the results: −2.1% in 30 days (Nifty 500: +1.0%).
  • Q1 FY26: Revenue ₹294 cr, EBITDA ₹34.0 cr, PAT ₹0.0 cr, EBITDA margin 11.6%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

TruAlt Bioenergy Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.